Portfolio Manager Factsheet

March 2018

Sarepta, Amicus and Regeneron were the top positive contributors to performance during the month. Biogen was weak due to continued scepticism around the company’s recently upsized trial of aducanumab in Alzheimer’s disease.

Read more »

The Biotech Growth Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers (IFAs) to retail private investors. The shares are excluded from the Financial Conduct Authority's (FCA's) restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.